Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2017 | 5 | 1 | 6 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 0 | 3 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. Chest. 2021 12; 160(6):2123-2134.
-
In silico drug repurposing in COVID-19: A network-based analysis. Biomed Pharmacother. 2021 Oct; 142:111954.
-
Increasing diversion of prescribed benzodiazepines and Z-drugs to new psychoactive substances. Clin Ter. 2021 Mar 15; 172(2):116-118.
-
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021 Mar; 271(2):249-258.
-
Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19? Folia Neuropathol. 2021; 59(2):113-120.
-
CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection. ACS Chem Neurosci. 2020 08 05; 11(15):2137-2144.
-
Does obesity and diabetes mellitus metastasize to the brain? "Metaboptosis" and implications for drug discovery and development. CNS Spectr. 2019 10; 24(5):467-469.
-
Drug Treatment of Clinically Isolated Syndrome. CNS Drugs. 2019 07; 33(7):659-676.
-
The Role of Docosahexaenoic Acid (DHA) on Cognitive Functions in Psychiatric Disorders. Nutrients. 2019 Apr 02; 11(4).
-
Protective effect of ginsenoside Rg1 on LPS-induced apoptosis of lung epithelial cells. Mol Immunol. 2021 08; 136:168-174.